Entry Point Capital, LLC Relay Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $188 Million
- Q2 2025
A detailed history of Entry Point Capital, LLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 46,959 shares of RLAY stock, worth $157,312. This represents 0.09% of its overall portfolio holdings.
Number of Shares
46,959
Previous 71,486
34.31%
Holding current value
$157,312
Previous $187,000
13.37%
% of portfolio
0.09%
Previous 0.09%
Shares
5 transactions
Others Institutions Holding RLAY
# of Institutions
222Shares Held
160MCall Options Held
153KPut Options Held
49.2K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$93.5 Million0.67% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.8MShares$36.3 Million0.07% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$35.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$31.4 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.1MShares$30.5 Million2.79% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $403M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...